Increasing evidence that the risks of rhAPC may outweigh its benefits

被引：51

作者：

Eichacker, Peter Q. ^{[1
]}

Natanson, Charles ^{[1
]}

机构：

[1] NIH, Dept Crit Care Med, Ctr Clin, Bethesda, MD 20892 USA

来源：

INTENSIVE CARE MEDICINE | 2007年 / 33卷 / 03期

关键词：

D O I：

10.1007/s00134-007-0556-8

中图分类号：

R4 [临床医学];

学科分类号：

1002 [临床医学]; 100602 [中西医结合临床];

摘要：

引用

收藏

页码：396 / 399

页数：4

相关论文

共 14 条

[1]

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death [J].

Abraham, E ;

Laterre, P ;

Garg, R ;

Levy, H ;

Talwar, D ;

Trzaskoma, BL ;

Francois, B ;

Guy, JS ;

Bruckmann, M ;

Rea-Neto, A ;

Rossaint, R ;

Perrotin, D ;

Sablotzki, A ;

Arkins, N ;

Utterback, BG ;

Macias, WL .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (13) :1332-1341

[2]

Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].

Bernard, GR ;

Vincent, JL ;

Laterre, P ;

LaRosa, SP ;

Dhainaut, JF ;

Lopez-Rodriguez, A ;

Steingrub, JS ;

Garber, GE ;

Helterbrand, JD ;

Ely, EW ;

Fisher, CJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709

[3]

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey [J].

Bertolini, Guido ;

Rossi, Carlotta ;

Anghileri, Abramo ;

Livigni, Sergio ;

Addis, Antonio ;

Poole, Daniele .

INTENSIVE CARE MEDICINE, 2007, 33 (03) :426-434

[4]

Substantiating the concerns about recombinant human activated protein C use in sepsis [J].

Deans, KJ ;

Minneci, PC ;

Banks, SM ;

Natanson, C ;

Eichacker, PQ .

CRITICAL CARE MEDICINE, 2004, 32 (12) :2542-2543

[5]

Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial [J].

Eichacker, PQ ;

Danner, RL ;

Suffredini, AF ;

Cui, XZ ;

Natanson, C .

CRITICAL CARE MEDICINE, 2005, 33 (10) :2426-2428

[6]

Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials [J].

Eichacker, PQ ;

Natanson, C .

CRITICAL CARE MEDICINE, 2003, 31 (01) :S94-S96

[7]

EISENBERG P, IMPORTANT DRUG WARIN

[8]

EISENBERG P, DISCONTINUATION STUD

[9]

Focus on research - First, gather the data [J].

Hunter, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (04) :329-331

[10]

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study [J].

Kanji, Salmaan ;

Perreault, Marc M. ;

Chant, Clarence ;

Williamson, David ;

Burry, Lisa .

INTENSIVE CARE MEDICINE, 2007, 33 (03) :517-523